Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 09 okt 2014 - 07:30

Statutaire naam Galapagos NV

Titel Galapagos presents novel cystic fibrosis combination therapy at NACFC

Bericht Mechelen, Belgium; 9 October 2014 - Galapagos NV (Euronext: GLPG) presents a poster today disclosing the discovery process for novel, complementary corrector series that restore the CFTR function in a new way at the North American Cystic Fibrosis Conference in Atlanta, USA. These novel corrector series, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos is among the first to pass this hurdle pre-clinically. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201410090000000004_Galapagos presenteert nieuwe combinatie medicijnen voor taaislijmziekte op CF conferentie.pdf (opens in a new window)

201410090000000004_Galapagos presents novel cystic fibrosis combination therapy at NACFC.pdf (opens in a new window)

Datum laatste update: 22 maart 2025